MAI Wealth Advisors »

Allogene Therapeutics shares owned by MAI Wealth Advisors

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by MAI Wealth Advisors from 13F filings

Historical chart of MAI Wealth Advisors investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by MAI Wealth Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by MAI Wealth Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $1.5k 1.1k 1.37
2025-09-30 $1.4k 1.1k 1.24
2025-06-30 $1.2k 1.1k 1.13
2025-03-31 $1.1k 719 1.46
2024-12-31 $2 1 2.00

More positions owned by MAI Wealth Advisors

Ishares Tr Core S&p500 Etf (IVV)
Spdr S&p 500 Etf Tr Call Call Option (Principal) (SPY)
Apple Call Call Option (Principal) (AAPL)
Microsoft Corp Call Call Option (Principal) (MSFT)
Ishares Tr Core S&p Mcp Etf (IJH)
Nvidia Corporation Call Call Option (Principal) (NVDA)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Alphabet Call Call Option (Principal) (GOOGL)
Amazon Call Call Option (Principal) (AMZN)
Invesco Qqq Tr Call Call Option (Principal) (QQQ)
Ishares Tr Core S&p Scp Etf (IJR)
Vanguard Specialized Funds Div App Etf (VIG)
Ishares Tr S&p 500 Val Etf (IVE)
Broadcom Call Call Option (Principal) (AVGO)
Ishares Tr Core Msci Eafe (IEFA)

View all positions for MAI Wealth Advisors

Top funds holding Allogene Therapeutics

Pfizer
Tpg Gp A
BlackRock
Citadel Advisors
Vanguard Group
PRIMECAP Management Company
Patient Square Capital
Geode Capital Management
Frazier Life Sciences Management
Woodline Partners
Millennium Management
Two Sigma Investments
Wildcat Capital Management
Two Sigma Advisers
State Street Corporation

View all funds holding Allogene Therapeutics